<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        15-828-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RAPAMUNE 1 MG Coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SIROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        495.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Ireland Pharmaceuticals" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Ireland Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants. It helps to control your body&rsquo;s immune system after you have received a kidney transplant.</p><p>&nbsp;</p><p>Rapamune is used in adults to prevent your body from rejecting transplanted kidneys and is normally used with other immunosuppressant medicines called corticosteroids and initially (the first 2 to 3&nbsp;months) with ciclosporin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Rapamune:</strong></p><p>&nbsp;</p><p><strong>- </strong>if you are allergic to sirolimus or any of the other ingredients of this medicine (listed in section 6).</p><p><em>&nbsp;</em></p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Rapamune</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any liver problems or have had a disease which may have affected your liver, please tell your doctor as this may affect the dose of Rapamune that you receive and may result in your having additional blood tests.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapamune, like other immunosuppressive medicines, may decrease your body&rsquo;s ability to fight infection, and may increase the risk of developing cancer of the lymphoid tissues and skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a body mass index (BMI) greater than 30&nbsp;kg/m<sup>2</sup>, you may be at increased risk of abnormal wound healing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are considered to be at high risk for kidney rejection, such as if you had a previous transplant that was lost to rejection.</p><p>&nbsp;</p><p>Your doctor will perform tests to monitor the levels of Rapamune in your blood. Your doctor will also perform tests to monitor your kidney function, your blood fat (cholesterol and/or triglycerides) levels and possibly your liver function, during treatment with Rapamune.</p><p>&nbsp;</p><p>Exposure to sunlight and UV light should be limited by covering your skin with clothing and using a sunscreen with a high protection factor because of the increased risk for skin cancer.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>&nbsp;</p><p>There is limited experience on the use of Rapamune in children and adolescents less than 18&nbsp;years of age. The use of Rapamune is not recommended in this population.</p><p>&nbsp;</p><p><strong>Other medicines and Rapamune</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Some medicines can interfere with the action of Rapamune and, therefore, dose adjustment of Rapamune may be required. In particular, you should inform your doctor or pharmacist if you are taking any of the following:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other immunosuppressant medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics or antifungal medicines used to treat infection e.g. clarithromycin, erythromycin, telithromycin, troleandomycin, rifabutin, clotrimazole, fluconazole, itraconazole. It is not recommended that Rapamune be taken with rifampicin, ketoconazole or voriconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any high blood pressure medicines or medicines for heart problems including nicardipine, verapamil and diltiazem.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti‑epileptic medicines including carbamazepine, phenobarbital, phenytoin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat ulcers or other gastrointestinal disorders such as cisapride, cimetidine, metoclopramide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bromocriptine (used in the treatment of Parkinson&rsquo;s disease and various hormonal disorders), danazol (used in the treatment of gynaecological disorders), or protease inhibitors (e.g., for HIV and hepatitis C such as ritonavir, indinavir, boceprevir, and telaprevir).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (<em>Hypericum perforatum</em>).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; letermovir (an antiviral medicine to prevent getting ill from cytomegalovirus).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannabidiol (uses amongst others include treatment of seizures).</p><p>&nbsp;</p><p>The use of live vaccines should be avoided with the use of Rapamune. Before vaccinations, please inform your doctor or pharmacist that you are receiving Rapamune.</p><p>&nbsp;</p><p>The use of Rapamune may lead to increased levels of cholesterol and triglycerides (blood fats) in your blood that may require treatment. Medicines known as &ldquo;statins&rdquo; and &ldquo;fibrates&rdquo; used to treat elevated cholesterol and triglycerides have been associated with an increased risk of muscle breakdown (rhabdomyolysis). Please inform your doctor if you are taking medicines to lower your blood fats.</p><p>&nbsp;</p><p>The combined use of Rapamune with angiotensin‑converting enzyme (ACE) inhibitors (a type of medicine used to lower blood pressure) may result in allergic reactions. Please inform your doctor if you are taking any of these medicines.</p><p>&nbsp;</p><p><strong>Rapamune with food and drink</strong></p><p>&nbsp;</p><p>Rapamune should be taken consistently, either with or without food. If you prefer to take Rapamune with food, then you should always take it with food. If you prefer to take Rapamune without food, then you should always take it without food. Food can affect the amount of medicine that gets into your bloodstream, and taking your medicine in a consistent way means that the blood levels of Rapamune remain more stable.</p><p>&nbsp;</p><p>Rapamune should not be taken with grapefruit juice.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast‑feeding and fertility</strong></p><p>&nbsp;</p><p>Rapamune should not be used during pregnancy unless clearly necessary. You must use an effective method of contraception during treatment with Rapamune and for 12&nbsp;weeks after treatment has stopped.&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not known whether Rapamune passes into breast milk. Patients taking Rapamune should discontinue breast‑feeding.</p><p>&nbsp;</p><p>RAPAMUNE may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.</p><p>&nbsp;</p><p>Decreased sperm count has been associated with the use of Rapamune and usually returns to normal once treatment is stopped.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Although Rapamune treatment is not expected to affect your ability to drive, if you have any concerns please consult your doctor.<strong> </strong></p><p>&nbsp;</p><p><strong>Rapamune contains lactose and sucrose</strong></p><p>&nbsp;</p><p>Rapamune contains 86.4 mg of lactose and up to 215.8 mg of sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor will decide exactly what dose of Rapamune you must take and how often to take it. Follow your doctor&rsquo;s instructions exactly, and never change the dose yourself.</p><p>&nbsp;</p><p>Rapamune is for oral use only. &nbsp;Do not crush, chew, or split the tablets. Inform your doctor if you have difficulty taking the tablet.</p><p>&nbsp;</p><p>Multiples of 0.5 mg tablets should not be used as a substitute for 1 mg and 2 mg tablets, as the different strengths are not directly interchangeable.</p><p>&nbsp;</p><p>Rapamune should be taken consistently, either with or without food.</p><p><u>&nbsp;</u></p><p><u>Kidney Transplant</u></p><p>Your doctor will give you an initial dose of 6&nbsp;mg as soon as possible after the kidney transplant operation. Then you will need to take 2&nbsp;mg of Rapamune each day, until otherwise directed by your doctor. Your dose will be adjusted depending on the level of Rapamune in your blood. Your doctor will need to perform blood tests to measure Rapamune concentrations.</p><p>&nbsp;</p><p>If you are also taking ciclosporin, then you must take the two medicines approximately 4&nbsp;hours apart.</p><p>&nbsp;</p><p>It is recommended that Rapamune be used first in combination with ciclosporin and corticosteroids. After 3&nbsp;months, your doctor may discontinue either Rapamune or ciclosporin, as it is not recommended that these medicines be taken together beyond this period.</p><p>&nbsp;</p><p><strong>If you take more Rapamune than you should</strong></p><p>&nbsp;</p><p>If you have taken more medicine than you were told to, contact a doctor or go to the nearest hospital emergency department as soon as possible. Always take the labelled blister with you, even if it is empty.</p><p>&nbsp;</p><p><strong>If you forget to take Rapamune</strong></p><p>&nbsp;</p><p>If you forget to take Rapamune, take it as soon as you remember, but not within 4&nbsp;hours of the next dose of ciclosporin. After that, continue to take your medicines as usual. Do not take a double dose to make up for a forgotten dose, and always take Rapamune and ciclosporin approximately 4&nbsp;hours apart. If you miss a dose of Rapamune completely, you should inform your doctor.</p><p>&nbsp;</p><p><strong>If you stop taking Rapamune</strong></p><p>&nbsp;</p><p>Do not stop taking Rapamune unless your doctor tells you to, as you risk losing your transplant.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>&nbsp;</p><p>You should <strong>see your doctor immediately</strong> if you experience symptoms, such as swollen face, tongue and/or back of the mouth (pharynx) and/or difficulties in breathing (angioedema), or a skin condition whereby the skin can peel off (exfoliative dermatitis). These may be symptoms of a serious allergic reaction.</p><p>&nbsp;</p><p><strong>Kidney damage with low blood cell counts (thrombocytopaenic purpura/haemolytic uraemic syndrome)</strong></p><p>&nbsp;</p><p>When taken with medicines called calcineurin inhibitors (ciclosporin or tacrolimus), Rapamune may increase the risk of kidney damage with low blood platelets and low red blood cell counts, with or without rash (thrombocytopaenic purpura/haemolytic uraemic syndrome). If you experience symptoms such as bruising or rash, changes in your urine, or changes in behaviour or any others that are serious, unusual or prolonged, contact your doctor.</p><p>&nbsp;</p><p><strong>Infections</strong></p><p>&nbsp;</p><p>Rapamune reduces your body&rsquo;s own defence mechanisms. Consequently your body will not be as good as normal at fighting infections. So if you are taking Rapamune, you may therefore catch more infections than usual, such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract (see list below). You should contact your doctor if you experience symptoms that are serious, unusual, or prolonged.</p><p>&nbsp;</p><p><strong>Side effect frequencies</strong></p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid collection around the kidney</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the body including hands and feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, diarrhoea, constipation, nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cells, low blood platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased fat in the blood (cholesterol and/or triglycerides), increased blood sugar, low blood potassium, low blood phosphorus, increased lactate dehydrogenase in the blood, increased creatinine in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia and other bacterial, viral, and fungal infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduced number of infection‑fighting cells in the blood (white blood cells)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal tests of liver function, elevated AST and/or ALT liver enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated protein in the urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menstrual disorders (including absent, infrequent or heavy periods)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow healing (this may include separation of the layers of a surgical wound or stitch line)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid heart rate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is a general tendency for fluid to collect in various tissues</p><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections (including life‑threatening infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth sores</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid collection in the abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney damage with low blood platelets and low red blood cell counts, with or without rash (haemolytic uraemic syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of a type of white blood cells called neutrophils</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deterioration of bone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation that may lead to lung damage, fluid around the lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovarian cysts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid collection in the sac around the heart, that in some cases may decrease the heart&#39;s ability to pump blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytomegalovirus infection</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the lymph tissue (lymphoma/post‑transplant lympho‑proliferative disorder), combined lowering of red blood cells, white blood cells and blood platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from the lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protein in the urine, occasionally severe and associated with side effects, such as swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Scarring in the kidney that may reduce kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too much fluid collecting in the tissues due to irregular lymph function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood platelets, with or without rash (thrombocytopaenic purpura)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reactions that can cause peeling of the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tuberculosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epstein-Barr virus infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infectious diarrhoea with <em>Clostridium difficile</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious liver damage</p><p>&nbsp;</p><p>Rare: may affect up to 1 in 1,000 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protein build‑up in the air sacs of the lungs that may interfere with breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reactions that can affect blood vessels (see above paragraph on allergic reactions)</p><p>&nbsp;</p><p>Not known: frequency cannot be estimated from the available data</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posterior reversible encephalopathy syndrome (PRES), a serious nervous system syndrome that has the following symptoms: headache, nausea, vomiting, confusion, seizures, and visual loss. Should any of these occur together, please contact your physician.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>store below 25˚C.</p><p>Keep the blister in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is sirolimus.</p><p>Each Rapamune 1&nbsp;mg coated tablet contains 1&nbsp;mg of sirolimus.</p><p>&nbsp;</p><p>The other ingredients are:</p><p><u>Tablet core</u>: lactose monohydrate, macrogol, magnesium stearate, talc</p><p><u>Tablet coating</u>: macrogol, glycerol monooleate, pharmaceutical glaze, calcium sulfate, microcrystalline cellulose, sucrose, titanium dioxide, poloxamer 188, a‑tocopherol, povidone, carnauba wax, printing ink (Shellac, iron Oxide Red, Propylene Glycol, Ammonium Hydroxide, Simethicone).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rapamune 1 mg is supplied to you as white coloured, triangular shaped coated tablets marked “RAPAMUNE 1 mg” on one side.

The tablets are supplied in blister packs of 30 and 100 tablets. Not all pack sizes may be marketed.

Not all pack sizes or strengths may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Europe MA EEIG, Belgium</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturedby:</strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Ireland Pharmaceuticals, Newbridge, Ireland</p><p>&nbsp;</p><p><strong>Packed and Released by :</strong></p><p>Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي راباميون على المادة الفعالة سيروليميس، التي تنتمي إلى مجموعة من الأدوية تُدعى &nbsp;مثبطات المناعة، وهو يساعد على التحكم في جهاز المناعة بجسمك بعد خضوعك لعملية زرع كلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم راباميون في البالغين لمنع الجسم من رفض الكلية المزروعة، وعادةً ما يُستخدم مع أدوية أخرى مثبطات للمناعة تدعى كورتكستيرويدز وفي البداية (خلال أول شهرين إلى 3 أشهر) مع سيكلوسبورين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال راباميون:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>- </strong>إذا كنت مصابًا بالحساسية تجاه سيروليميس أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL"><em>&nbsp;</em></p><p><strong>الاحتياطات عند استعمال راباميون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول راباميون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشكلات بالكبد أو سبق أن أصبت بمرض يُحتمل أن يكون قد أثّر على كبدك، يُرجى إخبار طبيبك حيث قد يؤثر ذلك على جرعة راباميون التي تتلقاها وقد يؤدي إلى خضوعك لفحوصات دم إضافية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقلل راباميون، مثله مثل الأدوية الأخرى ا مثبطة &nbsp;للمناعة، من قدرة جسمك على مقاومة العدوى وقد يزيد من خطورة الإصابة بسرطان الأنسجة الليمفاوية والجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مؤشر كتلة الجسم (BMI) لديك أكبر من ٣٠ كلجم/م<sup>٢</sup>، فقد يزداد خطر تعرضك لاعتلال التئام الجروح لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعد من الفئة المُعرضة لخطر مرتفع لرفض الجسم للكلى المزروعة، كأن تكون قد خضعت لعملية زرع سابقة آلت إلى الفشل نتيجة لرفض الجسم للعضو المزروع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يخضعك طبيبك لاختبارات لمراقبة مستويات راباميون في دمك. سيخضعك طبيبك أيضًا لاختبارات لمراقبة وظائف الكلى لديك ومستويات الدهون في دمك (الكوليسترول و/أو ثلاثيات الجليسريد) وربما أيضًا وظائف الكبد لديك، أثناء العلاج براباميون.</p><p dir="RTL">&nbsp;</p><p>ينبغي الحد من التعرض لأشعة الشمس والأشعة فوق البنفسجية عن طريق تغطية جلدك بالملابس واستخدام كريم واقٍ من الشمس ذي عامل حماية مرتفع، نظرًا لزيادة خطر الإصابة بسرطان الجلد.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقون </strong></p><p dir="RTL">هناك تجارب محدودة بشأن استخدام راباميون مع الأطفال والمراهقين الأصغر من ١٨ عامًا. لا يوصى باستخدام راباميون مع هذه الفئة.</p><p dir="RTL">&nbsp;</p><p><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتداخل بعض الأدوية مع عمل راباميون ولذلك قد يلزم إجراء تعديلات على جرعة راباميون. وبصفة خاصة، ينبغي عليك إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية أخرى كابتة للمناعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية أو الأدوية المضادة للفطريات المُستخدمة لعلاج العدوى، مثل كلاريثرومايسين، إريثرومايسين، تيليثرومايسين، ترولياندومايسين، ريفابوتين، كلوتريمازول، فلوكونازول، إيتراكونازول. ينصح بعدم تناول راباميون بالتزامن مع ريفامبيسين أو كيتوكونازول أو فوريكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية لعلاج ضغط الدم المرتفع أو الأدوية المستخدمة لعلاج مشكلات القلب بما في ذلك نيكارديبين وفيراباميل وديلتيازيم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للصرع بما في ذلك كاربامازيبين وفينوباربيتال وفينيتوين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج القرح أو الاضطرابات المعدية المعوية الأخرى مثل سيسابرايد، سيميتيدين، ميتوكلوبراميد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروموكريبتين (يُستخدم في علاج مرض باركنسون واضطرابات هرمونية متنوعة) أو دانازول (يُستخدم في علاج اضطرابات الجهاز التناسلي الأنثوي) أو مثبطات إنزيم البروتياز (على سبيل المثال، لعلاج فيروس نقص المناعة البشرية (HIV) والتهاب الكبد الوبائي C مثل ريتونافير وإندينافير وبوسيبريفير وتيلابريفير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (هايبريكوم بيرفوراتوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليتيرموفير (دواء مضاد للفيروسات لمنع المرض الناتج عن الفيروس المضخم للخلايا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانابيديول (تتضمن استخداماته علاج النوبات، من بين استخدامات أخرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تجنب استخدام اللقاحات الحية أثناء استخدام راباميون. قبل التطعيم، يُرجى إخبار طبيبك أو الصيدلي أنك تتلقى راباميون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي استخدام راباميون إلى زيادة مستويات الكوليسترول وثلاثيات الجليسريد (الدهون في الدم) في دمك، مما قد يتطلب علاجًا. ارتبطت الأدوية التي يُطلق عليها &quot;الستاتينات&quot; و&quot;الفيبرات&quot; المُستخدمة لعلاج ارتفاع مستويات الكوليسترول وثلاثيات الجليسريد، بزيادة خطر التعرض لانحلال العضلات (انحلال الربيدات). يُرجى إبلاغ طبيبك إذا كنت تتناول أدوية لتقليل الدهون بدمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن ينتج عن الاستخدام المتزامن لراباميون مع مثبطات الإنزيم المحول للأنجيوتنسين (ACE) (وهو نوع من الأدوية يُستخدم لخفض ضغط الدم) حدوث تفاعلات حساسية. يُرجى إبلاغ طبيبك إذا كنت تتناول أيًا من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p><strong>تناول راباميون مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تثبيت طريقة تناول راباميون، إما مع الطعام أو بدونه. إذا كنت تفضل تناول راباميون مع الطعام، ينبغي عليك إذًا تناوله دائمًا مع الطعام. أما إذا كنت تفضل تناول راباميون بدون طعام، ينبغي عليك إذًا تناوله دائمًا بدون طعام. قد يؤثر الطعام على كمية الدواء التي تصل إلى مجرى دمك، ويعني تناول دوائك بطريقة ثابتة أن مستويات راباميون في دمك تظل أكثر استقرارًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم تناول راباميون مع عصير الجريب فروت.</p><p dir="RTL">&nbsp;</p><p><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام راباميون أثناء الحمل ما لم تكن هناك ضرورة واضحة لذلك. يجب عليكِ استخدام وسيلة فعالة لمنع الحمل أثناء العلاج براباميون ولمدة ١٢ أسبوعًا بعد إيقاف العلاج. إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو إذا كنتِ تعتقدين أنكِ حاملًا أو كنتِ تخططين لإنجاب طفل، فتحدثي إلى طبيبكِ أو الصيدلي للمشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُعرف إذا ما كان راباميون يُفرز في حليب الأم أم لا. ينبغي على المريضات اللاتي يتناولن راباميون إيقاف الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر راباميون على الخصوبة لدى الإناث وقد يؤثر على قدرتكِ على الحمل. تحدثي إلى مقدم الرعاية الصحية الخاص بكِ إذا كان هذا مصدر قلق بالنسبة لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الربط بين تناقص تعداد الحيوانات المنوية واستخدام راباميون، وعادةً ما تعود إلى مستوياتها الطبيعية بمجرد إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p><strong>تأثير راباميون على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المتوقع أن يؤثر العلاج براباميون على قدرتك على القيادة، لكن إذا كان لديك أي مخاوف يُرجى استشارة طبيبك.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات راباميون</strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>يحتوي راباميون على اللاكتوز والسكروز</strong></p><p dir="RTL">يحتوي راباميون على ٨٦,٤ ملجم من اللاكتوز وما يصل إلى ٢١٥,٨ ملجم من السكروز. إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض السكريات، فاتصل به قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك جرعة راباميون التي يجب عليك تناولها تحديدًا وعدد مرات تكرار تناولها. اتبع تعليمات طبيبك بدقة ولا تغير الجرعة أبدًا من تلقاء نفسك.</p><p dir="RTL">راباميون مُخصص للاستعمال عن طريق الفم فقط. لا تسحق الأقراص أو تمضغها أو تقسمها. أبلغ طبيبك إذا وجدت صعوبة في تناول القرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام عدة أقراص ٠,٥ ملجم كبديل عن أقراص الـ١ ملجم أو الـ٢ ملجم، حيث إن التركيزات المختلفة غير قابلة لتحل محل بعضها البعض بشكل مباشر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تثبيت طريقة تناول راباميون، إما مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>زراعة الكلى</u></p><p dir="RTL">سيعطيك طبيبك جرعة مبدئية تبلغ ٦ ملجم في أسرع وقت ممكن بعد عملية زرع الكلية. ستحتاج بعد ذلك إلى تناول ٢ ملجم من راباميون كل يوم، حتى يوجهك طبيبك بخلاف ذلك. سوف يتم تعديل جرعتك وفقًا لمستوى راباميون في دمك. سيحتاج طبيبك لإجراء فحوصات دم لقياس تركيزات راباميون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت أيضًا تتناول سيكلوسبورين، يجب أن تفصل بين تناول الدواءين بـ٤ ساعات تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُنصح بتناول راباميون في بداية استخدامه بالتزامن مع سيكلوسبورينكورتكستيرويدز . بعد ٣ أشهر، قد يقوم طبيبك بإيقاف راباميون أو سيكلوسبورين، حيث يوصى بعدم تناول هذين الدواءين معًا لأكثر من هذه الفترة.</p><p dir="RTL">&nbsp;</p><p><strong>الجرعة الزائدة من راباميون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت كمية من الدواء أكبر مما وُصِف لك، فاتصل بطبيب أو توجه إلى قسم الطوارئ بأقرب مستشفى في أقرب وقت ممكن. احرص دومًا على أخذ شريط الدواء الذي يحمل المعلومات المُعرِّفة بالدواء معك حتى إذا كان فارغًا.</p><p dir="RTL">&nbsp;</p><p><strong>نسيان تناول جرعة راباميون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول راباميون، فتناوله بمجرد تذكرك، على ألا يكون ذلك خلال فترة الـ٤ ساعات السابقة لموعد جرعة سيكلوسبورين التالية. واستمر بعد ذلك في تناول أدويتك كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها، وافصل دائمًا بين تناول راباميون وسيكلوسبورين بنحو ٤ ساعات. إذا فاتتك جرعة راباميون تمامًا، ينبغي عليك إبلاغ طبيبك.</p><p dir="RTL">&nbsp;</p><p><strong>التوقف عن تناول راباميون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوقف عن تناول راباميون إلا إذا طلب منك طبيبك ذلك، حيث إنك بذلك تعرض نفسك لخطر خسارة العضو المزروع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك مزيد من الأسئلة بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، من الممكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p><strong>تفاعلات الحساسية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك <strong>زيارة طبيبك فورًا</strong> إذا أصبت بأعراض مثل، تورم الوجه و/أو اللسان و/أو الجزء الخلفي من الفم (البلعوم) و/أو صعوبات في التنفس (الوذمة الوعائية) أو حالة جلدية يمكن أن تؤدي إلى تقشر الجلد (التهاب الجلد التقشري). قد تكون هذه أعراضًا لتفاعل حساسية خطير.</p><p dir="RTL">&nbsp;</p><p><strong>تلف الكلى المصحوب بتعداد منخفض لخلايا الدم (فرفريِّة نقص الصفيحات الدموية/متلازمة انحلال الدم اليوريمية)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند تناول راباميون بالتزامن مع أدوية تُسمى مثبطات الكالسينيورين (سيكلوسبورين أو تاكروليموس)، قد يزيد راباميون من خطر تلف الكلى المصحوب بتعداد منخفض للصفيحات الدموية وتعداد منخفض لخلايا الدم الحمراء، المصحوب أو غير المصحوب بطفح جلدي (فرفرية نقص الصفيحات الدموية/متلازمة انحلال الدم اليوريمية). إذا ظهرت عليك أعراض مثل التكدم أو الطفح الجلدي أو تغيرات في بولك أو تغيرات في السلوك أو أي أعراض أخرى خطيرة أو غير معتادة أو مُستمرة لمدة طويلة؛ فاتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p><strong>العدوى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يقلل راباميون من آليات جسمك الدفاعية. وبالتالي لن يكافح جسمك العدوى بنفس كفاءته وهو في حالته الطبيعية. ولذلك، إذا كنت تتناول راباميون، فقد تصاب بالعدوى أكثر من المعتاد، مثل عدوى الجلد والفم والمعدة والأمعاء والرئتين والمسالك البولية (انظر القائمة أدناه). ينبغي أن تتصل بطبيبك إذا أصبت بأعراض خطيرة أو غير معتادة أو مستمرة لمدة طويلة.</p><p dir="RTL">&nbsp;</p><p><strong>معدلات تكرار الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع السوائل حول الكلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجسم بما في ذلك اليدين والقدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالمعدة، إسهال، إمساك، غثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة خلايا الدم الحمراء، قلة الصفيحات الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدهون في الدم (الكوليسترول و/أو ثلاثيات الجليسريد)، زيادة نسبة السكر في الدم، نسبة البوتاسيوم منخفضة في الدم، نسبة الفوسفور منخفضة في الدم، زيادة نازعة هيدروجين اللاكتات في الدم، زيادة الكرياتينين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي وأنواع أخرى من العدوى البكتيرية والفيروسية والفطرية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الخلايا المقاومة للعدوى في الدم (خلايا الدم البيضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات وظائف الكبد، ارتفاع مستويات الإنزيمين الكبديين ناقلة أمين الأسبارتات (AST) و/أو ناقلة أمين الألانين (ALT)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البروتين في البول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الحيض (بما في ذلك غياب الدورة الشهرية أو عدم انتظامها أو كثافة تدفقها)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء الالتئام (قد يتضمن هذا انفصال طبقات الشقوق الجراحية أو موضع الخياطة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع معدل نبضات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوجد ميل عام لتجمع السوائل في الأنسجة المختلفة</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى (بما في ذلك أنواع العدوى المهددة للحياة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الساقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الرئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع السوائل في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكلى المصحوب بتعداد الصفيحات الدموية منخفض وتعداد خلايا الدم الحمراء منخفض، المصحوب أو غير المصحوب بطفح جلدي (متلازمة انحلال الدم اليوريمية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات نوع من خلايا الدم البيضاء يدعى العدلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور العظام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الذي يمكن أن يؤدي إلى تلف الرئة، تجمع سوائل حول الرئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكيُّسات المبيضية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع السوائل في الغلاف المحيط بالقلب، مما يمكن أن يؤدي في بعض الحالات إلى إضعاف قدرة القلب على ضخ الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس النطاقي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الفيروس المضخم للخلايا</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان النسيج الليمفاوي (سرطان الغدد الليمفاوية/الاضطراب التكاثري الليمفاوي التالي للزرع)، خفض شامل لخلايا الدم الحمراء والبيضاء والصفيحات الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بروتين في البول، الذي أحيانًا ما يكون شديدًا ومصحوبًا بآثار جانبية، مثل التورم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تندُّب الكلى الذي يمكن أن يضعف من وظيفتها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع لكمية مفرطة من السوائل في الأنسجة نتيجة لاختلال الوظائف الليمفاوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات الدموية، المصحوب أو غير المصحوب بطفح جلدي (فرفرية نقص الصفيحات الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الخطيرة التي يمكن أن تسبب تقشر الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروس إبشتاين-بار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الذي تتسبب به عدوى المطثية العسيرة (كلوستريديوم ديفيسيل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف خطير بالكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل 1000 شخص</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم البروتين في الأَكياس الهوائية في الرئتين مما قد يؤثر على التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الخطيرة التي يمكن أن تؤثر على الأوعية الدموية (انظر الفقرة الخاصة بتفاعلات الحساسية أعلاه)</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة الاعتلال الدماغي الخلفي القابل للعكس (PRES)، وهي متلازمة خطيرة تصيب الجهاز العصبي وتتميز بالأعراض التالية: صداع، وغثيان، وقيء، وتشوش، ونوبات، وفقدان الرؤية. إذا حدث أي من هذه الآثار معًا، يُرجى الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الممرض، الصيدلي. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><em>&nbsp;</em></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على شرائط البليستر والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن الدواء في درجة حرارة اقل من ٢٥ درجة مئوية.</p><p dir="RTL">احفظ شرائط البليستر في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيروليميس.</p><p dir="RTL">سيروليميسيحتوي كل قرص مغلف من راباميون 1 ملجم على 1 ملجم من سيروليميس.</p><p dir="RTL">سيروليميس</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><u>قلب القرص</u>: لاكتوز أحادي الهيدرات، ماكروجول، ستيارات المغنيسيوم، تلك</p><p dir="RTL"><u>غلاف القرص</u>: ماكروجول، جليسرول أحادي الأوليات، مادة ملمعة صيدلانية، كبريتات الكالسيوم، سليولوز بلوري مكروي، سكروز، ثاني أكسيد التيتانيوم، بولوكسامر 188، a‑توكوفيرول، بوفيدون، شمع الكارنوبا، حبر طباعة (صمغ اللك، أكسيد الحديد الأحمر، بروبيلين جليكول، هيدروكسيد الأمونيوم، سيميثيكون).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توريد راباميون 1 ملجم إليك في صورة أقراص مغلفة مثلثة الشكل بيضاء، تحمل على أحد جانبيها &quot;RAPAMUNE 1&nbsp;mg&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر الأقراص في عبوات ذات شرائط الدواء &nbsp;تحتوي على 30 قرصًا و100 قرص. قد لا يتم طرح جميع أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تُطرح جميع التركيزات أو أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Pfizer Europe MA EEIG, Belgium، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تم التصنيع بواسطة:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Pfizer Ireland Pharmaceuticals, Newbridge, Ireland، أيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">تمت التعبئة والتوزيع بواسطة:</p><p dir="RTL">Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany،</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rapamune 1 mg coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rapamune 1 mg coated tablets
Each coated tablet contains 1 mg sirolimus.
Excipients with known effect
Rapamune 1 mg coated tablets
Each tablet contains 86.4 mg of lactose monohydrate and 215.8 mg of sucrose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet (tablet).
Rapamune 1 mg coated tablets
White-coloured, triangular-shaped, coated tablet marked “RAPAMUNE 1 mg” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate<br />immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially<br />in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune<br />may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion<br />can be progressively discontinued (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Prophylaxis of organ rejection</u></em></p><p>&nbsp;</p><p>Treatment should be initiated by and remain under the guidance of an appropriately qualified specialist in transplantation.</p><p>&nbsp;</p><p><em>Initial therapy (2 to 3 months post‑transplantation)</em></p><p>The usual dose regimen for Rapamune is a 6&nbsp;mg single oral loading dose, administered as soon as possible after transplantation, followed by 2&nbsp;mg once daily until results of therapeutic monitoring of the medicinal product are available (see <em>Therapeutic monitoring of the medicinal product and dose adjustment</em>). The Rapamune dose should then be individualised to obtain whole blood trough levels of 4 to 12&nbsp;ng/mL (chromatographic assay). Rapamune therapy should be optimised with a tapering regimen of steroids and ciclosporin microemulsion. Suggested ciclosporin trough concentration ranges for the first 2‑3&nbsp;months after transplantation are 150‑400&nbsp;ng/mL (monoclonal assay or equivalent technique) (see section 4.5<em>)</em>.</p><p>&nbsp;</p><p>To minimise variability, Rapamune should be taken at the same time in relation to ciclosporin, 4&nbsp;hours after the ciclosporin dose, and consistently either with or without food (see section 5.2).</p><p>&nbsp;</p><p><em>Maintenance therapy</em></p><p>Ciclosporin should be progressively discontinued over 4 to 8&nbsp;weeks, and the Rapamune dose should be adjusted to obtain whole blood trough levels of 12 to 20&nbsp;ng/mL (chromatographic assay; see <em>Therapeutic monitoring of the medicinal product and dose adjustment</em>). Rapamune should be given with corticosteroids. In patients for whom ciclosporin withdrawal is either unsuccessful or cannot be attempted, the combination of ciclosporin and Rapamune should not be maintained for more than 3&nbsp;months post‑transplantation. In such patients, when clinically appropriate, Rapamune should be discontinued and an alternative immunosuppressive regimen instituted.</p><p>&nbsp;</p><p><em>Therapeutic monitoring of the medicinal product and dose adjustment </em></p><p>Whole blood sirolimus levels should be closely monitored in the following populations<em>: </em></p><p>(1) in patients with hepatic impairment</p><p>(2) when inducers or inhibitors of CYP3A4 and/or P-glycoprotein (P-gp) are concurrently administered and after their discontinuation (see section 4.5) and/or</p><p>(3) if ciclosporin dosing is markedly reduced or discontinued, as these populations are most likely to have special dosing requirements.</p><p>&nbsp;</p><p>Therapeutic monitoring of the medicinal product should not be the sole basis for adjusting sirolimus therapy. Careful attention should be made to clinical signs/symptoms, tissue biopsies, and laboratory parameters.</p><p><u>&nbsp;</u></p><p>Most patients who received 2&nbsp;mg of Rapamune 4&nbsp;hours after ciclosporin had whole blood trough concentrations of sirolimus within the 4 to 12&nbsp;ng/mL target range (expressed as chromatographic assay values). Optimal therapy requires therapeutic concentration monitoring of the medicinal product in all patients.</p><p>&nbsp;</p><p>Optimally, adjustments in Rapamune dose should be based on more than a single trough level obtained more than 5&nbsp;days after a previous dosing change.</p><p>&nbsp;</p><p>Patients can be switched from Rapamune oral solution to the tablet formulation on a mg per mg basis. It is recommended that a trough concentration be taken 1 or 2&nbsp;weeks after switching formulations or tablet strength to confirm that the trough concentration is within the recommended target range.</p><p><u>&nbsp;</u></p><p>Following the discontinuation of ciclosporin therapy, a target trough range of 12 to 20&nbsp;ng/mL (chromatographic assay) is recommended. Ciclosporin inhibits the metabolism of sirolimus, and consequently sirolimus levels will decrease when ciclosporin is discontinued, unless the sirolimus dose is increased. On average, the sirolimus dose will need to be 4‑fold higher to account for both the absence of the pharmacokinetic interaction (2‑fold increase) and the augmented immunosuppressive requirement in the absence of ciclosporin (2‑fold increase). The rate at which the dose of sirolimus is increased should correspond to the rate of ciclosporin elimination.</p><p>&nbsp;</p><p>If further dose adjustment(s) are required during maintenance therapy (after discontinuation of ciclosporin), in most patients these adjustments can be based on simple proportion: new Rapamune dose&nbsp;=&nbsp;current dose x (target concentration/current concentration). A loading dose should be considered in addition to a new maintenance dose when it is necessary to considerably increase sirolimus trough concentrations: Rapamune loading dose = 3 x (new maintenance dose &ndash; current maintenance dose). The maximum Rapamune dose administered on any day should not exceed 40&nbsp;mg. If an estimated daily dose exceeds 40&nbsp;mg due to the addition of a loading dose, the loading dose should be administered over 2&nbsp;days. Sirolimus trough concentrations should be monitored at least 3 to 4&nbsp;days after a loading dose(s).</p><p>&nbsp;</p><p>The recommended 24‑hour trough concentration ranges for sirolimus are based on chromatographic methods. Several assay methodologies have been used to measure the whole blood concentrations of sirolimus. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. The concentration values obtained by these different methodologies are not interchangeable. All sirolimus concentrations reported in this Summary of Product Characteristics were either measured using chromatographic methods or have been converted to chromatographic method equivalents. Adjustments to the targeted range should be made according to the assay being utilised to determine the sirolimus trough concentrations. Since results are assay and laboratory dependent, and the results may change over time, adjustment to the targeted therapeutic range must be made with a detailed knowledge of the site‑specific assay used. Physicians should therefore remain continuously informed by responsible representatives for their local laboratory on the performance of the locally used method for concentration determination of sirolimus.</p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Black population</em></p><p>There is limited information indicating that Black renal transplant recipients (predominantly African‑American) require higher doses and trough levels of sirolimus to achieve the same efficacy as observed in non‑Black patients. The efficacy and safety data are too limited to allow specific recommendations for use of sirolimus in Black recipients.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>Clinical studies with Rapamune oral solution did not include a sufficient number of patients above 65&nbsp;years of age to determine whether they will respond differently than younger patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>No dose adjustment is required (see section 5.2).</p><p><strong><em>&nbsp;</em></strong></p><p><em>Hepatic impairment </em></p><p>The clearance of sirolimus may be reduced in patients with impaired hepatic function (see section 5.2). In patients with severe hepatic impairment, it is recommended that the maintenance dose of Rapamune be reduced by approximately one‑half.</p><p>&nbsp;</p><p>It is recommended that sirolimus whole blood trough levels be closely monitored in patients with impaired hepatic function (see <em>Therapeutic monitoring of the medicinal product and dose adjustment</em>). It is not necessary to modify the Rapamune loading dose.</p><p>&nbsp;</p><p>In patients with severe hepatic impairment, monitoring should be performed every 5 to 7&nbsp;days until 3&nbsp;consecutive trough levels have shown stable concentrations of sirolimus after dose adjustment or after loading dose due to the delay in reaching steady‑state because of the prolonged half‑life.</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Rapamune in children and adolescents less than 18&nbsp;years of age have not been established. Currently available data are described in sections 4.8, 5.1 and 5.2, but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Rapamune is for oral use only.</p><p>&nbsp;</p><p>Bioavailability has not been determined for tablets after they have been crushed, chewed or split, and therefore this cannot be recommended.</p><p>&nbsp;</p><p>To minimise variability, Rapamune should consistently be taken either with or without food.</p><p>&nbsp;</p><p>Grapefruit juice should be avoided (see section 4.5).</p><p>&nbsp;</p><p>Multiples of 0.5&nbsp;mg tablets should not be used as a substitute for the 1&nbsp;mg tablet or for other strengths (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rapamune has not been adequately studied in renal transplant patients at high immunological risk, therefore use is not recommended in this group of patients (see section 5.1).</p><p>&nbsp;</p><p>In renal transplant patients with delayed graft function, sirolimus may delay recovery of renal function.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis, have been associated with the administration of sirolimus (see&nbsp;section 4.8).</p><p>&nbsp;</p><p><u>Concomitant therapy</u></p><p>&nbsp;</p><p><em>Immunosuppressive agents (Renal transplant patients only)</em></p><p>Sirolimus has been administered concurrently with the following agents in clinical studies: tacrolimus, ciclosporin, azathioprine, mycophenolate mofetil, corticosteroids and cytotoxic antibodies. Sirolimus in combination with other immunosuppressive agents has not been extensively investigated.</p><p>&nbsp;</p><p>Renal function should be monitored during concomitant administration of Rapamune and ciclosporin. Appropriate adjustment of the immunosuppression regimen should be considered in patients with elevated serum creatinine levels. Caution should be exercised when co‑administering other agents that are known to have a deleterious effect on renal function.</p><p>&nbsp;</p><p>Patients treated with ciclosporin and Rapamune beyond 3&nbsp;months had higher serum creatinine levels and lower calculated glomerular filtration rates compared to patients treated with ciclosporin and placebo or azathioprine controls. Patients who were successfully withdrawn from ciclosporin had lower serum creatinine levels and higher calculated glomerular filtration rates, as well as lower incidence of malignancy, compared to patients remaining on ciclosporin. The continued co‑administration of ciclosporin and Rapamune as maintenance therapy cannot be recommended.</p><p>&nbsp;</p><p>Based on information from subsequent clinical studies, the use of Rapamune, mycophenolate mofetil, and corticosteroids, in combination with IL‑2 receptor antibody (IL2R Ab) induction, is not recommended in the <em>de novo</em> renal transplant setting (see section 5.1).</p><p>&nbsp;</p><p>Periodic quantitative monitoring of urinary protein excretion is recommended. In a study evaluating conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant patients, increased urinary protein excretion was commonly observed at 6 to 24&nbsp;months after conversion to Rapamune (see section 5.1). New onset nephrosis (nephrotic syndrome) was also reported in 2% of the patients in the study (see section 4.8). Based on information from an open-label randomised study, conversion from the calcineurin inhibitor tacrolimus to Rapamune in maintenance renal transplant patients was associated with an unfavourable safety profile without efficacy benefit and can therefore not be recommended (see section 5.1).</p><p>&nbsp;</p><p>The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor‑induced haemolytic uraemic syndrome/thrombotic thrombocytopaenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).</p><p>&nbsp;</p><p><em>HMG-CoA reductase inhibitors</em></p><p>In clinical studies, the concomitant administration of Rapamune and HMG‑CoA reductase inhibitors and/or fibrates was well‑tolerated. During Rapamune therapy with or without CsA, patients should be monitored for elevated lipids, and patients administered an HMG‑CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse reactions, as described in the respective Summary of Product Characteristics of these agents.</p><p>&nbsp;</p><p><em>Cytochrome P450 isozymes</em><em> and P-glycoprotein</em></p><p>Co‑administration of sirolimus with strong inhibitors of CYP3A4 and/or the multidrug efflux pump</p><p>P-glycoprotein (P-gp) (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) may increase sirolimus blood levels and is not recommended.</p><p>&nbsp;</p><p>Co-administration with strong inducers of CYP3A4 and/or P-gp (such as rifampin, rifabutin) is not recommended.</p><p>&nbsp;</p><p>If co-administration of inducers or inhibitors of CYP3A4 and/or P-gp cannot be avoided, it is</p><p>recommended that sirolimus whole blood trough concentrations and the clinical condition of the</p><p>patient be monitored while they are concurrently administered with sirolimus and after their</p><p>discontinuation. Dose adjustments of sirolimus may be required (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p><em>Angioedema</em></p><p>The concomitant administration of Rapamune and angiotensin‑converting enzyme (ACE) inhibitors has resulted in angioneurotic oedema‑type reactions. Elevated sirolimus levels, for example due to interaction with strong CYP3A4 inhibitors, (with/without concomitant ACE inhibitors) may also potentiate angioedema (see section 4.5). In some cases, the angioedema has resolved upon discontinuation or dose reduction of Rapamune.</p><p>&nbsp;</p><p>Increased rates of biopsy confirmed acute rejection (BCAR) in renal transplant patients have been observed with concomitant use of sirolimus with ACE inhibitors (see section 5.1). Patients receiving sirolimus should be monitored closely if taking ACE inhibitors concomitantly.</p><p>&nbsp;</p><p><em>Vaccination</em></p><p>Immunosuppressants may affect response to vaccination. During treatment with immunosuppressants, including Rapamune, vaccination may be less effective. The use of live vaccines should be avoided during treatment with Rapamune.</p><p>&nbsp;</p><p><u>Malignancy</u></p><p>&nbsp;</p><p>Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression (see section 4.8). As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections, and sepsis.</p><p>&nbsp;</p><p>Among these conditions in renal transplant patients are BK virus‑associated nephropathy and JC virus‑associated progressive multifocal leukoencephalopathy (PML). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.</p><p>&nbsp;</p><p>Cases of <em>Pneumocystis carinii</em> pneumonia have been reported in renal transplant patients not receiving antimicrobial prophylaxis. Therefore, antimicrobial prophylaxis for <em>Pneumocystis carinii</em> pneumonia should be administered for the first 12&nbsp;months following transplantation.</p><p>&nbsp;</p><p>Cytomegalovirus (CMV) prophylaxis is recommended for 3&nbsp;months after renal transplantation, particularly for patients at increased risk for CMV disease.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>In hepatically impaired patients, it is recommended that sirolimus whole blood trough levels be closely monitored. In patients with severe hepatic impairment, reduction in maintenance dose by one-half is recommended based on decreased clearance (see sections 4.2 and 5.2). Since half‑life is prolonged in these patients, therapeutic monitoring of the medicinal product after a loading dose or a change of dose should be performed for a prolonged period of time until stable concentrations are reached (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Lung and liver transplant populations</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore such use is not recommended.</p><p>&nbsp;</p><p>In two clinical studies in <em>de novo</em> liver transplant patients, the use of sirolimus plus ciclosporin or tacrolimus was associated with an increase in hepatic artery thrombosis, mostly leading to graft loss or death.</p><p>&nbsp;</p><p>A clinical study in liver transplant patients randomised to conversion from a calcineurin inhibitor (CNI)‑based regimen to a sirolimus‑based regimen versus continuation of a CNI‑based regimen 6‑144&nbsp;months post‑liver transplantation failed to demonstrate superiority in baseline‑adjusted GFR at 12&nbsp;months (-4.45&nbsp;mL/min and -3.07&nbsp;mL/min, respectively). The study also failed to demonstrate non‑inferiority of the rate of combined graft loss, missing survival data, or death for the sirolimus conversion group compared to the CNI continuation group.&nbsp;The rate of death in the sirolimus conversion group was higher than the CNI continuation group, although the rates were not significantly different. The rates of premature study discontinuation, adverse events overall (and infections, specifically), and biopsy‑proven acute liver graft rejection at 12&nbsp;months were all significantly greater in the sirolimus conversion group compared to the CNI continuation group.</p><p>&nbsp;</p><p>Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <em>de novo</em> lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.</p><p>&nbsp;</p><p><u>Systemic effects</u></p><p><u>&nbsp;</u></p><p>There have been reports of impaired or delayed wound healing in patients receiving Rapamune, including lymphocele in renal transplant patients and wound dehiscence. Patients with a body mass index (BMI) greater than 30&nbsp;kg/m<sup>2</sup> may be at increased risk of abnormal wound healing based on data from the medical literature.</p><p>&nbsp;</p><p>There have also been reports of fluid accumulation, including peripheral oedema, lymphoedema, pleural effusion and pericardial effusions (including haemodynamically significant effusions in children and adults), in patients receiving Rapamune.</p><p>&nbsp;</p><p>The use of Rapamune was associated with increased serum cholesterol and triglycerides that may require treatment. Patients administered Rapamune should be monitored for hyperlipidaemia using laboratory tests and if hyperlipidaemia is detected, subsequent interventions such as diet, exercise, and lipid‑lowering agents should be initiated. The risk/benefit should be considered in patients with established hyperlipidaemia before initiating an immunosuppressive regimen, including Rapamune. Similarly the risk/benefit of continued Rapamune therapy should be re‑evaluated in patients with severe refractory hyperlipidaemia.</p><p>&nbsp;</p><p><u>Sucrose and lactose </u></p><p><u>&nbsp;</u></p><p><em>Sucrose</em></p><p>Patients with rare hereditary problems of fructose intolerance, glucose‑galactose malabsorption or sucrase‑isomaltase insufficiency should not take this medicine.</p><p>&nbsp;</p><p><em>Lactose</em></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose‑galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver. Sirolimus is also a substrate for the multidrug efflux pump, P‑glycoprotein (P‑gp) located in the small intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of sirolimus and decrease sirolimus levels. Co‑administration of sirolimus with strong inhibitors of CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Rifampicin (CYP3A4 inducer)</u></p><p>&nbsp;</p><p>Administration of multiple doses of rifampicin decreased sirolimus whole blood concentrations following a single 10&nbsp;mg dose of Rapamune oral solution. Rifampicin increased the clearance of sirolimus by approximately 5.5‑fold and decreased AUC and C<sub>max</sub> by approximately 82% and 71%, respectively. Co‑administration of sirolimus and rifampicin is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Ketoconazole (CYP3A4 inhibitor)</u></p><p>&nbsp;</p><p>Multiple‑dose ketoconazole administration significantly affected the rate and extent of absorption and sirolimus exposure from Rapamune oral solution as reflected by increases in sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC of 4.4‑fold, 1.4‑fold, and 10.9‑fold, respectively. Co‑administration of sirolimus and ketoconazole is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Voriconazole (CYP3A4 inhibitor)</u></p><p>&nbsp;</p><p>Co‑administration of sirolimus (2&nbsp;mg single dose) with multiple‑dose administration of oral voriconazole (400&nbsp;mg every 12&nbsp;hours for 1&nbsp;day, then 100&nbsp;mg every 12&nbsp;hours for 8&nbsp;days) in healthy subjects has been reported to increase sirolimus C<sub>max</sub> and AUC by an average of 7‑fold and 11‑fold, respectively. Co‑administration of sirolimus and voriconazole is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Diltiazem (CYP3A4 inhibitor)</u></p><p>&nbsp;</p><p>The simultaneous oral administration of 10&nbsp;mg of Rapamune oral solution and 120&nbsp;mg of diltiazem significantly affected the bioavailability of sirolimus. Sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC were increased 1.4‑fold, 1.3‑fold, and 1.6‑fold, respectively. Sirolimus did not affect the pharmacokinetics of either diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem. If diltiazem is administered, sirolimus blood levels should be monitored and a dose adjustment may be necessary.</p><p>&nbsp;</p><p><u>Verapamil (CYP3A4 inhibitor)</u></p><p>&nbsp;</p><p>Multiple‑dose administration of verapamil and sirolimus oral solution significantly affected the rate and extent of absorption of both medicinal products. Whole blood sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC were increased 2.3‑fold, 1.1‑fold, and 2.2‑fold, respectively. Plasma S‑(-) verapamil C<sub>max</sub> and AUC were both increased 1.5‑fold, and t<sub>max</sub> was decreased 24%. Sirolimus levels should be monitored, and appropriate dose reductions of both medicinal products should be considered.</p><p>&nbsp;</p><p><u>Erythromycin (CYP3A4 inhibitor)</u></p><p>&nbsp;</p><p>Multiple‑dose administration of erythromycin and sirolimus oral solution significantly increased the rate and extent of absorption of both medicinal products. Whole blood sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC were increased 4.4‑fold, 1.4‑fold, and 4.2‑fold, respectively. The C<sub>max</sub>, t<sub>max</sub>, and AUC of plasma erythromycin base were increased 1.6‑fold, 1.3‑fold, and 1.7‑fold, respectively. Sirolimus levels should be monitored and appropriate dose reductions of both medicinal products should be considered.</p><p>&nbsp;</p><p><u>Ciclosporin (CYP3A4 substrate)</u></p><p>&nbsp;</p><p>The rate and extent of sirolimus absorption was significantly increased by ciclosporin A (CsA). Sirolimus administered concomitantly (5&nbsp;mg), and at 2&nbsp;hours (5&nbsp;mg) and 4&nbsp;hours (10&nbsp;mg) after CsA (300&nbsp;mg), resulted in increased sirolimus AUC by approximately 183%, 141% and 80%, respectively. The effect of CsA was also reflected by increases in sirolimus C<sub>max</sub> and t<sub>max</sub>. When given 2&nbsp;hours before CsA administration, sirolimus C<sub>max</sub> and AUC were not affected. Single‑dose sirolimus did not affect the pharmacokinetics of ciclosporin (microemulsion) in healthy volunteers when administered simultaneously or 4&nbsp;hours apart. It is recommended that Rapamune be administered 4&nbsp;hours after ciclosporin (microemulsion).</p><p>&nbsp;</p><p><u>Cannabidiol (P-gp inhibitor)</u></p><p>There have been reports of increased blood levels of sirolimus during concomitant use with cannabidiol. Co-administration of cannabidiol with another orally administered mTOR inhibitor in a</p><p>healthy volunteer study led to an increase in exposure to the mTOR inhibitor of approximately 2.5-fold for both Cmax and AUC, due to inhibition of intestinal P-gp efflux by cannabidiol. Caution should be used when cannabidiol and Rapamune are co-administered, closely monitoring for side effects. Monitor sirolimus blood levels and adjust the dose as needed (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>No clinically significant pharmacokinetic interaction was observed between Rapamune oral solution and 0.3&nbsp;mg norgestrel/0.03&nbsp;mg ethinyl estradiol. Although the results of a single‑dose interaction study with an oral contraceptive suggest the lack of a pharmacokinetic interaction, the results cannot exclude the possibility of changes in the pharmacokinetics that might affect the efficacy of the oral contraceptive during long‑term treatment with Rapamune.</p><p>&nbsp;</p><p><u>Other possible interactions</u></p><p>&nbsp;</p><p>Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels. Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and letermovir.</p><p>&nbsp;</p><p>Inducers of CYP3A4 may increase the metabolism of sirolimus and decrease sirolimus blood levels (e.g., St. John&#39;s Wort (<em>Hypericum perforatum</em>),<em> </em>anticonvulsants: carbamazepine, phenobarbital, phenytoin).</p><p>&nbsp;</p><p>Although sirolimus inhibits human liver microsomal cytochrome P<sub>450</sub> CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 <em>in vitro</em>, the active substance is not expected to inhibit the activity of these isozymes <em>in&nbsp;vivo</em> since the sirolimus concentrations necessary to produce inhibition are much higher than those observed in patients receiving therapeutic doses of Rapamune. Inhibitors of P‑gp may decrease the efflux of sirolimus from intestinal cells and increase sirolimus levels.</p><p>&nbsp;</p><p>Grapefruit juice affects CYP3A4‑mediated metabolism, and should therefore be avoided.</p><p>&nbsp;</p><p>Pharmacokinetic interactions may be observed with gastrointestinal prokinetic agents, such as cisapride and metoclopramide.</p><p>&nbsp;</p><p>No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine, prednisolone, and trimethoprim/sulfamethoxazole.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Effective contraception must be used during Rapamune therapy and for 12&nbsp;weeks after Rapamune has been stopped (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of sirolimus in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Rapamune should not be used during pregnancy unless clearly necessary. Effective contraception must be used during Rapamune therapy and for 12&nbsp;weeks after Rapamune has been stopped.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Following administration of radiolabelled sirolimus, radioactivity is excreted in the milk of lactating rats. It is unknown whether sirolimus is excreted in human milk. Because of the potential for adverse reactions in breast‑fed infants from sirolimus, breast‑feeding should be discontinued during treatment with Rapamune.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Impairments of sperm parameters have been observed among some patients treated with Rapamune. These effects have been reversible upon discontinuation of Rapamune in most cases (see section 5.3). Ovarian cysts and menstrual disorders (including amenorrhea and menorrhagia) have been reported in females with the use of sirolimus. Azoospermia has been reported in males with the use of sirolimus and has been reversible upon discontinuation of sirolimus in most cases.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rapamune has no known influence on the ability to drive and use machines. No studies on the effects on the ability to drive and use machines have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Undesirable effects observed with prophylaxis of organ rejection in renal transplantation</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions (occurring in &gt;10% of patients) are thrombocytopaenia, anaemia, pyrexia, hypertension, hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral oedema, arthralgia, acne, diarrhoea, pain, constipation, nausea, headache, increased blood creatinine, and increased blood lactate dehydrogenase (LDH).</p><p>&nbsp;</p><p>The incidence of any adverse reaction(s) may increase as the trough sirolimus level increases.</p><p>&nbsp;</p><p>The following list of adverse reactions is based on experience from clinical studies and on postmarketing experience.</p><p>&nbsp;</p><p>Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Most patients were on immunosuppressive regimens, which included Rapamune in combination with other immunosuppressive agents.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p>Rare</p><p>(&ge;1/10,000 to</p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p><strong>(cannot be estimated from available data)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia;</p><p>Fungal infection;</p><p>Viral infection;</p><p>Bacterial infection;</p><p>Herpes simplex infection;</p><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Sepsis;</p><p>Pyelonephritis; Cytomegalo-virus infection; Herpes zoster caused by the varicella zoster virus</p></td><td style="vertical-align:top"><p><em>Clostridium difficile</em> colitis;</p><p>Mycobacterial infection (including tuberculosis);</p><p>Epstein-Barr virus infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer*</p></td><td style="vertical-align:top"><p>Lymphoma*; Malignant melanoma*; Post-transplant lymphoproli-ferative disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neuroendocrine carcinoma of the skin*</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocyto-paenia;</p><p>Anaemia; Leucopenia</p></td><td style="vertical-align:top"><p>Haemolytic uraemic syndrome; Neutropaenia</p></td><td style="vertical-align:top"><p>Pancyto-paenia; Thrombotic thrombo-cytopaenic purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyper-sensitivity (including angioedema, anaphylactic reaction, and anaphylactoid reaction)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hypokalaemia; Hypophospha-taemia; Hyperlipidaemia (including hypercholeste-rolaemia); Hyperglycaemia; Hypertriglyceri-daemia; Diabetes mellitus</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Posterior reversible encephalopathy syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;Pericardial effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypertension;</p><p>Lymphocele</p></td><td style="vertical-align:top"><p>Venous thrombosis (including deep vein thrombosis)</p></td><td style="vertical-align:top"><p>Lymphoedema</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism;</p><p>Pneumonitis*;</p><p>Pleural effusion;</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Pulmonary haemorrhage</p></td><td style="vertical-align:top"><p>Alveolar proteinosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain; Constipation;</p><p>Diarrhoea;</p><p>Nausea</p></td><td style="vertical-align:top"><p>Pancreatitis; Stomatitis;</p><p>Ascites</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Liver function test abnormal (including alanine aminotransferase increased and aspartate amino-transferase increased)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic failure*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash;</p><p>Acne</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative</p></td><td style="vertical-align:top"><p>Hypersen-sitivity vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Osteonecrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Proteinuria</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nephrotic syndrome (see section 4.4); Focal segmental glomerulo-sclerosis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Menstrual disorder</p><p>(including amenorrhoea and menorrhagia)</p></td><td style="vertical-align:top"><p>Ovarian cyst</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Oedema;</p><p>Oedema peripheral;</p><p>Pyrexia;</p><p>Pain;</p><p>Impaired healing*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Blood lactate dehydrogenase increased;</p><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*See section below.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Immunosuppression increases the susceptibility to the development of lymphoma and other malignancies, particularly of the skin (see section 4.4).</p><p>&nbsp;</p><p>Cases of BK virus‑associated nephropathy, as well as cases of JC virus‑associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Rapamune.</p><p>&nbsp;</p><p>Hepatoxicity has been reported. The risk may increase as the trough sirolimus level increases. Rare reports of fatal hepatic necrosis have been reported with elevated trough sirolimus levels.</p><p>&nbsp;</p><p>Cases of interstitial lung disease (including pneumonitis and infrequently bronchiolitis obliterans organising pneumonia (BOOP) and pulmonary fibrosis), some fatal, with no identified infectious aetiology have occurred in patients receiving immunosuppressive regimens including Rapamune. In some cases, the interstitial lung disease has resolved upon discontinuation or dose reduction of Rapamune. The risk may be increased as the trough sirolimus level increases.</p><p>&nbsp;</p><p>Impaired healing following transplant surgery has been reported, including fascial dehiscence, incisional hernia, and anastomotic disruption (e.g., wound, vascular, airway, ureteral, biliary).</p><p>&nbsp;</p><p>Impairments of sperm parameters have been observed among some patients treated with Rapamune. These effects have been reversible upon discontinuation of Rapamune in most cases (see section 5.3).</p><p>&nbsp;</p><p>In patients with delayed graft function, sirolimus may delay recovery of renal function.</p><p>&nbsp;</p><p>The concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor‑induced HUS/TTP/TMA.</p><p>&nbsp;</p><p>Focal segmental glomerulosclerosis has been reported.</p><p>&nbsp;</p><p>There have also been reports of fluid accumulation, including peripheral oedema, lymphoedema, pleural effusion and pericardial effusions (including haemodynamically significant effusions in children and adults) in patients receiving Rapamune.</p><p>&nbsp;</p><p>In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (target levels of 12‑20&nbsp;ng/mL in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n=90) with a baseline glomerular filtration rate of less than 40&nbsp;mL/min (see section 5.1). There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this sirolimus treatment arm (n=60, median time post‑transplant 36&nbsp;months).</p><p>&nbsp;</p><p>Ovarian cysts and menstrual disorders (including amenorrhoea and menorrhagia) have been reported. Patients with symptomatic ovarian cysts should be referred for further evaluation. The incidence of ovarian cysts may be higher in premenopausal females compared to postmenopausal females. In some cases, ovarian cysts and these menstrual disorders have resolved upon discontinuation of Rapamune.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Controlled clinical studies with posology comparable to that currently indicated for the use of Rapamune in adults have not been conducted in children or adolescents below 18&nbsp;years of age.</p><p>&nbsp;</p><p>Safety was assessed in a controlled clinical study enrolling renal transplant patients below 18&nbsp;years of age considered of high immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy (see section 5.1). The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and cholesterol), and urinary tract infections. The treatment regimen studied (continuous use of Rapamune in combination with calcineurin inhibitor) is not indicated for adult or paediatric patients (see section 4.1).</p><p>&nbsp;</p><p>In another study enrolling renal transplant patients 20&nbsp;years of age and below that was intended to assess the safety of progressive corticosteroid withdrawal (beginning at six months post‑transplantation) from an immunosuppressive regimen initiated at transplantation that included full‑dose immunosuppression with both Rapamune and a calcineurin inhibitor in combination with basiliximab induction, of the 274 patients enrolled, 19 (6.9%) were reported to have developed post‑transplant lymphoproliferative disorder (PTLD). Among 89 patients known to be Epstein-Barr virus (EBV) seronegative prior to transplantation, 13 (15.6%) were reported to have developed PTLD. All patients who developed PTLD were aged below 18&nbsp;years.</p><p>&nbsp;</p><p>There is insufficient experience to recommend the use of Rapamune in children and adolescents (see section 4.2).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p>To Report side effects</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At present, there is minimal experience with overdose. One patient experienced an episode of atrial fibrillation after ingestion of 150&nbsp;mg of Rapamune. In general, the adverse effects of overdose are consistent with those listed in section 4.8. General supportive measures should be initiated in all cases of overdose. Based on the poor aqueous solubility and high erythrocyte and plasma protein binding of Rapamune, it is anticipated that Rapamune will not be dialysable to any significant extent.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants,</p><p>ATC code: L04AA10.</p><p>&nbsp;</p><p>Sirolimus inhibits T‑cell activation induced by most stimuli, by blocking calcium‑dependent and calcium‑independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents. Experimental evidence suggests that sirolimus binds to the specific cytosolic protein FKPB‑12, and that the FKPB&nbsp;12‑sirolimus complex inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a critical kinase for cell cycle progression. The inhibition of mTOR results in blockage of several specific signal transduction pathways. The net result is the inhibition of lymphocyte activation, which results in immunosuppression.</p><p>&nbsp;</p><p>In animals, sirolimus has a direct effect on T- and B‑cell activation, suppressing immune‑mediated reactions, such as allograft rejection.</p><p>&nbsp;</p><p><u>Clinical studies</u></p><p>&nbsp;</p><p><em><u>Prophylaxis of Organ Rejection</u></em></p><p>&nbsp;</p><p>Patients at low to moderate immunological risk were studied in the phase 3 ciclosporin elimination‑Rapamune maintenance study, which included patients receiving a renal allograft from a cadaveric or living donor. In addition, re‑transplant recipients whose previous grafts survived for at least 6&nbsp;months after transplantation were included. Ciclosporin was not withdrawn in patients experiencing Banff Grade 3&nbsp;acute rejection episodes, who were dialysis‑dependent, who had a serum creatinine higher than&nbsp;400&nbsp;mmol/L, or who had inadequate renal function to support ciclosporin withdrawal. Patients at high immunological risk of graft loss were not studied in sufficient number in the ciclosporin elimination‑Rapamune maintenance studies and are not recommended for this treatment regimen.</p><p>&nbsp;</p><p>At 12, 24 and 36&nbsp;months, graft and patient survival were similar for both groups. At 48&nbsp;months, there was a statistically significant difference in graft survival in favour of the Rapamune following ciclosporin elimination group compared to the Rapamune with ciclosporin therapy group (including and excluding loss to follow‑up). There was a significantly higher rate of first biopsy‑proven rejection in the ciclosporin elimination group compared to the ciclosporin maintenance group during the period post‑randomisation to 12&nbsp;months (9.8% vs. 4.2%, respectively). Thereafter, the difference between the two groups was not significant.</p><p>&nbsp;</p><p>The mean calculated glomerular filtration rate (GFR) at 12, 24, 36, 48 and 60&nbsp;months was significantly higher for patients receiving Rapamune following ciclosporin elimination than for those in the Rapamune with ciclosporin therapy group. Based upon the analysis of data from 36&nbsp;months and beyond, which showed a growing difference in graft survival and renal function, as well as significantly lower blood pressure in the ciclosporin elimination group, it was decided to discontinue subjects from the Rapamune with ciclosporin group. By 60&nbsp;months, the incidence of non‑skin malignancies was significantly higher in the cohort who continued ciclosporin as compared with the cohort who had ciclosporin withdrawn (8.4%&nbsp;vs. 3.8%, respectively). For skin carcinoma, the median time to first occurrence was significantly delayed.</p><p>&nbsp;</p><p>The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant patients (6‑120&nbsp;months after transplantation) was assessed in a randomised, multicentre, controlled trial, stratified by calculated GFR at baseline (20‑40 mL/min vs. above 40&nbsp;mL/min). Concomitant immunosuppressive agents included mycophenolate mofetil, azathioprine, and corticosteroids. Enrollment in the patient stratum with baseline calculated GFR below 40&nbsp;mL/min was discontinued due to an imbalance in safety events (see section 4.8).</p><p>&nbsp;</p><p>In the patient stratum with baseline calculated GFR above 40&nbsp;mL/min, renal function was not improved overall. The rates of acute rejection, graft loss, and death were similar at 1 and 2&nbsp;years. Treatment emergent adverse events occurred more frequently during the first 6&nbsp;months after Rapamune conversion. In the stratum with baseline calculated GFR above 40&nbsp;mL/min, the mean and median urinary protein to creatinine ratios were significantly higher in the Rapamune conversion group as compared to those of the calcineurin inhibitors continuation group at 24&nbsp;months (see section&nbsp;4.4). New onset nephrosis (nephrotic syndrome) was also reported (see section 4.8).</p><p>&nbsp;</p><p>At 2&nbsp;years, the rate of non‑melanoma skin malignancies was significantly lower in the Rapamune conversion group as compared to the calcineurin inhibitors continuation group (1.8% and 6.9%). In a subset of the study patients with a baseline GFR above 40&nbsp;mL/min and normal urinary protein excretion, calculated GFR was higher at 1 and 2&nbsp;years in patients converted to Rapamune than for the corresponding subset of calcineurin inhibitor continuation patients. The rates of acute rejection, graft loss, and death were similar, but urinary protein excretion was increased in the Rapamune treatment arm of this subset.</p><p>&nbsp;</p><p>In an open-label, randomised, comparative, multi-centre study where renal transplant patients were either converted from tacrolimus to sirolimus 3 to 5 months post-transplant or remained on tacrolimus, there was no significant difference in renal function at 2 years. There were more adverse events (99.2% vs. 91.1%, p=0.002*) and more discontinuations from the treatment due to adverse events (26.7% vs. 4.1%, p&lt;0.001*) in the group converted to sirolimus compared to the tacrolimus group. The incidence of biopsy confirmed acute rejection was higher (p=0.020*) for patients in the sirolimus group (11, 8.4%) compared to the tacrolimus group (2, 1.6%) through 2 years; most rejections were mild in severity (8 of 9 [89%] T-cell BCAR, 2 of 4 [50%] antibody mediated BCAR) in the sirolimus group. Patients who had both antibody-mediated rejection and T-cell-mediated rejection on the same biopsy were counted once for each category. More patients converted to sirolimus developed new onset diabetes mellitus defined as 30 days or longer of continuous or at least 25 days non-stop (without gap) use of any diabetic treatment after randomisation, a fasting glucose &ge;126 mg/dL or a non-fasting glucose &ge;200 mg/dL after randomisation (18.3% vs. 5.6%, p=0.025*). A lower incidence of squamous cell carcinoma of the skin was observed in the sirolimus group (0% vs. 4.9%). *Note: p-values not controlled for multiple testing.</p><p>&nbsp;</p><p>In two multi‑centre clinical studies, <em>de novo</em> renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), corticosteroids, and an IL‑2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with a calcineurin inhibitor, MMF, corticosteroids, and an IL‑2 receptor antagonist (see section 4.4).&nbsp; Renal function was not better in the treatment arms with <em>de novo</em> sirolimus without a calcineurin inhibitor. An abbreviated dosing schedule of daclizumab was used in one of the studies.</p><p>&nbsp;</p><p>In a randomised, comparative evaluation of ramipril versus placebo for the prevention of proteinuria in kidney transplant patients converted from calcineurin inhibitors to sirolimus, a difference in the number of patients with BCAR through 52&nbsp;weeks was observed [13 (9.5%) vs. 5 (3.2%), respectively; p = 0.073]. Patients initiated on ramipril 10&nbsp;mg had a higher rate of BCAR (15%) compared to patients initiated on ramipril 5&nbsp;mg (5%). Most rejections occurred within the first six months following conversion and were mild in severity; no graft losses were reported during the study (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Rapamune was assessed in a 36‑month controlled clinical study enrolling renal transplant patients below 18&nbsp;years of age considered at high‑immunologic risk, defined as having a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy. Subjects were to receive Rapamune (sirolimus target concentrations of 5 to 15&nbsp;ng/mL) in combination with a calcineurin inhibitor and corticosteroids or to receive calcineurin‑inhibitor‑based immunosuppression without Rapamune. The Rapamune group failed to demonstrate superiority to the control group in terms of the first occurrence of biopsy confirmed acute rejection, graft loss, or death. One death occurred in each group. The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and total cholesterol), and urinary tract infections (see section 4.8).</p><p>&nbsp;</p><p>An unacceptably high frequency of PTLD was seen in a paediatric clinical transplant study when full‑dose Rapamune was administered to children and adolescents in addition to full‑dose calcineurin inhibitors with basiliximab and corticosteroids (see section 4.8).</p><p>&nbsp;</p><p>In a retrospective review of hepatic veno‑occlusive disease (VOD) in patients who underwent myeloablative stem cell transplantation using cyclosphophamide and total body irradiation, an increased incidence of hepatic VOD was observed in patients treated with Rapamune, especially with concomitant use of methotrexate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Much of the general pharmacokinetic information was obtained using the Rapamune oral solution, which is summarised first. Information directly related to the tablet formulation is summarised specifically in the Oral tablet section.</p><p>&nbsp;</p><p><u>Oral solution</u></p><p>&nbsp;</p><p>Following administration of the Rapamune oral solution, sirolimus is rapidly absorbed, with a time to peak concentration of 1&nbsp;hour in healthy subjects receiving single doses and 2&nbsp;hours in patients with stable renal allografts receiving multiple doses. The systemic availability of sirolimus in combination with simultaneously administered ciclosporin (Sandimune) is approximately 14%. Upon repeated administration, the average blood concentration of sirolimus is increased approximately 3‑fold. The terminal half‑life in stable renal transplant patients after multiple oral doses was 62 <!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 16&nbsp;hours. The effective half‑life, however, is shorter and mean steady‑state concentrations were achieved after 5 to 7&nbsp;days. The blood to plasma ratio (B/P) of 36&nbsp;indicates that sirolimus is extensively partitioned into formed blood elements.</p><p>&nbsp;</p><p>Sirolimus is a substrate for both cytochrome P450 IIIA4 (CYP3A4) and P‑glycoprotein. Sirolimus is extensively metabolised by O‑demethylation and/or hydroxylation. Seven major metabolites, including hydroxyl, demethyl, and hydroxydemethyl, are identifiable in whole blood. Sirolimus is the major component in human whole blood and contributes to greater than 90% of the immunosuppressive activity. After a single dose of [<sup>14</sup>C] sirolimus in healthy volunteers, the majority (91.1%) of radioactivity was recovered from the faeces, and only a minor amount (2.2%) was excreted in urine.</p><p>&nbsp;</p><p>Clinical studies of Rapamune did not include a sufficient number of patients above 65&nbsp;years of age to determine whether they will respond differently than younger patients. Sirolimus trough concentration data in 35 renal transplant patients above 65&nbsp;years of age were similar to those in the adult population (n=822) from 18 to 65&nbsp;years of age.</p><p>&nbsp;</p><p>In paediatric patients on dialysis (30% to 50% reduction in glomerular filtration rate) within age ranges of 5 to 11&nbsp;years and 12 to 18&nbsp;years, the mean weight‑normalised CL/F was larger for younger paediatric patients (580&nbsp;mL/h/kg) than for older paediatric patients (450&nbsp;mL/h/kg) as compared with adults (287&nbsp;mL/h/kg). There was a large variability for individuals within the age groups.</p><p>&nbsp;</p><p>Sirolimus concentrations were measured in concentration‑controlled studies of paediatric renal‑transplant patients who were also receiving ciclosporin and corticosteroids. The target for trough concentrations was 10‑20&nbsp;ng/mL. At steady‑state, 8 children aged 6‑11&nbsp;years received mean &plusmn; SD doses of 1.75 &plusmn; 0.71&nbsp;mg/day (0.064 &plusmn; 0.018&nbsp;mg/kg, 1.65 &plusmn; 0.43&nbsp;mg/m<sup>2</sup>) while 14 adolescents aged 12‑18&nbsp;years received mean &plusmn; SD doses of 2.79 &plusmn; 1.25&nbsp;mg/day (0.053 &plusmn; 0.0150&nbsp;mg/kg, 1.86 &plusmn; 0.61&nbsp;mg/m<sup>2</sup>). The younger children had a higher weight‑normalised CL/F (214 mL/h/kg) compared with the adolescents (136 mL/h/kg). These data indicate that younger children might require higher bodyweight‑adjusted doses than adolescents and adults to achieve similar target concentrations. However, the development of such special dosing recommendations for children requires more data to be definitely confirmed.</p><p>&nbsp;</p><p>In mild and moderate hepatically impaired patients (Child‑Pugh classification A or B), mean values for sirolimus AUC and t<sub>1/2</sub> were increased 61% and 43%, respectively, and CL/F was decreased 33% compared to normal healthy subjects. In severe hepatically impaired patients (Child‑Pugh classification C), mean values for sirolimus AUC and t<sub>1/2</sub> were increased 210% and 170%, respectively, and CL/F was decreased by 67% compared to normal healthy subjects. The longer half‑lives observed in hepatically impaired patients delay reaching steady-state.</p><p><u>&nbsp;</u></p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>&nbsp;</p><p>The pharmacokinetics of sirolimus were similar in various populations with renal function ranging from normal to absent (dialysis patients).</p><p>&nbsp;</p><p><u>Oral tablet</u></p><p>&nbsp;</p><p>The 0.5&nbsp;mg tablet is not fully bioequivalent to the 1&nbsp;mg, 2&nbsp;mg and 5&nbsp;mg tablets when comparing C<sub>max</sub>. Multiples of the 0.5&nbsp;mg tablets should therefore not be used as a substitute for other tablet strengths.</p><p>&nbsp;</p><p>In healthy subjects, the mean extent of bioavailability of sirolimus after single‑dose administration of the tablet formulation is about 27% higher relative to the oral solution. The mean C<sub>max</sub> was decreased by 35%, and mean t<sub>max</sub> increased by 82%. The difference in bioavailability was less marked upon steady‑state administration to renal transplant recipients, and therapeutic equivalence has been demonstrated in a randomised study of 477&nbsp;patients. When switching patients between oral solution and tablet formulations, it is recommended to give the same dose and to verify the sirolimus trough concentration 1 to 2&nbsp;weeks later to assure that it remains within recommended target ranges. Also, when switching between different tablet strengths, verification of trough concentrations is recommended.</p><p>&nbsp;</p><p>In 24&nbsp;healthy volunteers receiving Rapamune tablets with a high‑fat meal, C<sub>max</sub>, t<sub>max</sub> and AUC showed increases of 65%, 32%, and 23%, respectively. To minimise variability, Rapamune tablets should be taken consistently with or without food. Grapefruit juice affects CYP3A4‑mediated metabolism and must, therefore, be avoided.</p><p>&nbsp;</p><p>Sirolimus concentrations, following the administration of Rapamune tablets (5&nbsp;mg) to healthy subjects as single doses are dose proportional between 5 and 40&nbsp;mg.</p><p>&nbsp;</p><p>Clinical studies of Rapamune did not include a sufficient number of patients above 65&nbsp;years of age to determine whether they will respond differently than younger patients. Rapamune tablets administered to 12&nbsp;renal transplant patients above 65&nbsp;years of age gave similar results to adult patients (n=167) 18 to 65&nbsp;years of age.</p><p>&nbsp;</p><p><em>Initial Therapy (2 to 3 months post-transplant)</em>: In most patients receiving Rapamune tablets with a loading dose of 6&nbsp;mg followed by an initial maintenance dose of 2&nbsp;mg, whole blood sirolimus trough concentrations rapidly achieved steady‑state concentrations within the recommended target range (4 to 12&nbsp;ng/mL, chromatographic assay). Sirolimus pharmacokinetic parameters following daily doses of 2&nbsp;mg Rapamune tablets administered in combination with ciclosporin microemulsion (4&nbsp;hours prior to Rapamune tablets) and corticosteroids in 13&nbsp;renal transplant patients, based on data collected at months 1 and 3 after transplantation, were: C<sub>min,ss</sub> 7.39 <!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 2.18&nbsp;ng/mL; C<sub>max,ss</sub> 15.0 <!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 4.9&nbsp;ng/mL; t<sub>max,ss</sub> 3.46 <!--[if supportFields]><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span>symbol 177 \f
&quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 2.40 hours; AUC<!--[if supportFields]><sub><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
116 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span></sub><![endif]--><sub>t</sub><!--[if supportFields]><sub><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></sub><![endif]--><sub>,ss</sub> 230 <!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 67&nbsp;ng.h/mL; CL/F/WT, 139 <!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 63&nbsp;mL/h/kg (parameters calculated from LC‑MS/MS assay results). The corresponding results for the oral solution in the same clinical study were C<sub>min,ss</sub> 5.40 &plusmn; 2.50&nbsp;ng/mL, C<sub>max,ss </sub>14.4&nbsp;&plusmn;&nbsp;5.3&nbsp;ng/mL, t<sub>max,ss </sub>2.12 &plusmn; 0.84 hours, AUC<!--[if supportFields]><sub><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
116 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span></sub><![endif]--><sub>t</sub><!--[if supportFields]><sub><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></sub><![endif]--><sub>,ss</sub> 194&nbsp;&plusmn; 78&nbsp;ng.h/mL, CL/F/W 173&nbsp;&plusmn; 50&nbsp;mL/h/kg. Whole blood trough sirolimus concentrations, as measured by LC/MS/MS, were significantly correlated (r<sup>2</sup>=0.85) with AUC<sub>t</sub><sub>,ss</sub>.</p><p>&nbsp;</p><p>Based on monitoring in all patients during the period of concomitant therapy with ciclosporin, mean (10<sup>th</sup>, 90<sup>th</sup> percentiles) troughs (expressed as chromatographic assay values) and daily doses were 8.6&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->&nbsp;3.0&nbsp;ng/mL&nbsp;(5.0 to 13&nbsp;ng/mL) and 2.1 <!--[if supportFields]><span lang=EN-GB
style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 0.70&nbsp;mg (1.5 to 2.7&nbsp;mg), respectively (see section 4.2).</p><p>&nbsp;</p><p><em>Maintenance therapy</em>: From month 3 to month 12, following discontinuation of ciclosporin, mean (10<sup>th</sup>, 90<sup>th</sup> percentiles) troughs (expressed as chromatographic assay values) and daily doses were 19&nbsp;<!--[if supportFields]><span lang=EN-GB
style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->&nbsp;4.1&nbsp;ng/mL&nbsp;(14 to 24&nbsp;ng/mL) and 8.2 <!--[if supportFields]><span lang=EN-GB
style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>symbol
177 \f &quot;Symbol&quot; \s 11<span style='mso-element:field-separator'></span></span><![endif]-->&plusmn;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> 4.2&nbsp;mg (3.6 to 13.6&nbsp;mg), respectively (see section 4.2). Therefore, the sirolimus dose was approximately 4‑fold higher to account for both the absence of the pharmacokinetic interaction with ciclosporin (2‑fold increase) and the augmented immunosuppressive requirement in the absence of ciclosporin (2‑fold increase).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use, were as follows: pancreatic islet cell vacuolation, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and calluses, hepatic haematopoiesis, and pulmonary phospholipidosis.</p><p>&nbsp;</p><p>Sirolimus was not mutagenic in the <em>in vitro</em> bacterial reverse mutation assays, the Chinese Hamster Ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the <em>in&nbsp;vivo</em> mouse micronucleus assay.</p><p>&nbsp;</p><p>Carcinogenicity studies conducted in mouse and rat showed increased incidences of lymphomas (male and female mouse), hepatocellular adenoma and carcinoma (male mouse) and granulocytic leukaemia (female mouse). It is known that malignancies (lymphoma) secondary to the chronic use of immunosuppressive agents can occur and have been reported in patients in rare instances. In mouse, chronic ulcerative skin lesions were increased. The changes may be related to chronic immunosuppression. In rat, testicular interstitial cell adenomas were likely indicative of a species‑dependent response to lutenising hormone levels and are usually considered of limited clinical relevance.</p><p>&nbsp;</p><p>In reproduction toxicity studies decreased fertility in male rats was observed. Partly reversible reductions in sperm counts were reported in a 13‑week rat study. Reductions in testicular weights and/or histological lesions (e.g., tubular atrophy and tubular giant cells) were observed in rats and in a monkey study. In rats, sirolimus caused embryo/foetotoxicity that was manifested as mortality and reduced foetal weights (with associated delays in skeletal ossification) (see section 4.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>&nbsp;</p><p>Lactose monohydrate</p><p>Macrogol</p><p>Magnesium stearate</p><p>Talc</p><p>&nbsp;</p><p>Tablet coating:</p><p>&nbsp;</p><p>Macrogol</p><p>Glycerol monooleate</p><p>Pharmaceutical glaze (shellac)</p><p>Calcium sulfate</p><p>Microcrystalline cellulose</p><p>Sucrose</p><p>Titanium dioxide</p><p>Poloxamer 188</p><p>a‑tocopherol</p><p>Povidone</p><p>Carnauba wax</p><p>Ink-Red Opacode S-1-15095</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

Do not use Rapamune after the expiry date which is stated on the Blister / Bottle label after EXP:. The expiry date refers to the last day of that month.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&ordm;C.</p><p>&nbsp;</p><p>Keep the blister in the outer carton in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear polyvinyl chloride (PVC)/polyethylene (PE)/polychlorotrifluoroethylene (Aclar) aluminium blister packages of 30 and 100&nbsp;tablets.</p><p>Not all pack sizes or strenghts may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG, Belgium 

MANUFACTURED BY:

Pfizer Ireland Pharmaceuticals, Newbridge, Ireland

PACKED AND RELEASED BY :
Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>